Roche Forecast, price target & analysts
Roche Target price 2024 - Analyst rating & recommendation
Roche Classifications & Recommendation:
Roche Target price
| Target price | CHF268.53 |
| Course | CHF248.50 |
| Price potential | 8.06% |
| Number of estimates | 19 |
| 19 Analysts have issued a price target Roche 2025 . The average Roche target price is CHF268.53. This is 8.06% higher than the current share price. The highest price target is CHF428.00 72.23% , the lowest is CHF210.00 15.49% . | |
| A rating was issued by 23 analysts: 8 Analysts recommend Roche to buy, 11 to hold and 4 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
| Analyst estimates: Analysts believe that the Roche share has an average upside potential 2025 of 8.06% . Most analysts recommend the Roche share at Hold. |
Sales and margin forecast 2024, 2025 to 2028
| Dec '23 |
2024 Forecast |
|
|---|---|---|
| Turnover Billion CHF | 58.72 | 60.87 |
| 7.21% | 3.66% | |
| EBITDA margin | 33.76% | 37.25% |
| 2.89% | 10.34% | |
| Net margin | 19.54% | 21.67% |
| 0.14% | 10.91% |
20 Analysts have issued a sales forecast Roche 2024 . The average Roche sales estimate is CHF60.9b . This is 3.66% higher than the turnover of the last 12 months(TTM). The highest sales forecast is CHF62.8b 6.96% , the lowest is CHF59.2b 0.80% .
This results in the following potential growth figures:
Sales forecast
| 2023 | CHF58.7b | 7.21% |
|---|---|---|
| 2024 | CHF60.9b | 3.66% |
| 2025 | CHF64.5b | 5.89% |
| 2026 | CHF67.3b | 4.40% |
| 2027 | CHF70.2b | 4.26% |
| 2028 | CHF72.6b | 3.49% |
18 Analysts have issued an Roche EBITDA forecast 2024. The average Roche EBITDA estimate is CHF22.7b . This is 14.37% higher than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is CHF24.8b 25.06% , the lowest is CHF20.2b 2.03% .
This results in the following potential growth figures and future EBITDA margins:
EBITDA forecast
| 2023 | CHF19.8b | 9.89% |
|---|---|---|
| 2024 | CHF22.7b | 14.37% |
| 2025 | CHF24.4b | 7.70% |
| 2026 | CHF25.7b | 5.15% |
| 2027 | CHF26.9b | 4.69% |
| 2028 | CHF28.0b | 4.35% |
EBITDA margin
| 2023 | 33.76% | 2.89% |
|---|---|---|
| 2024 | 37.25% | 10.34% |
| 2025 | 37.89% | 1.72% |
| 2026 | 38.16% | 0.71% |
| 2027 | 38.32% | 0.42% |
| 2028 | 38.64% | 0.84% |
14 Roche Analysts have issued a net profit forecast 2024. The average Roche net profit estimate is CHF13.2b . This is 14.91% higher than the net profit for the last 12 months(TTM). The highest net profit forecast is CHF14.6b 27.33% , the lowest is CHF10.8b 6.11% .
This results in the following potential growth figures and future net margins:
Net profit forecast
| 2023 | CHF11.5b | 7.34% |
|---|---|---|
| 2024 | CHF13.2b | 14.99% |
| 2025 | CHF14.6b | 10.76% |
| 2026 | CHF15.7b | 7.50% |
| 2027 | CHF17.1b | 8.92% |
| 2028 | CHF17.9b | 4.70% |
Net margin
| 2023 | 19.54% | 0.14% |
|---|---|---|
| 2024 | 21.67% | 10.91% |
| 2025 | 22.67% | 4.61% |
| 2026 | 23.34% | 2.96% |
| 2027 | 24.39% | 4.50% |
| 2028 | 24.67% | 1.15% |
Earnings per share, P/E ratio and EV/sales forecast 2024, 2025 to 2028
| Dec '23 |
2024 Forecast |
|
|---|---|---|
| Earnings per share CHF | 14.39 | 16.55 |
| 7.34% | 15.01% | |
| P/E ratio | 15.02 | |
| EV/Sales | 3.65 |
14 Analysts have issued a Roche forecast for earnings per share. The average Roche <a href=/blog/eps>EPS is CHF16.55 . This is 14.93% higher than earnings per share in the financial year 2023. The highest <a href=/blog/eps>EPS forecast is CHF18.34 27.36% , the lowest is CHF13.52 6.11% .
This results in the following potential growth figures and future valuations:
Earnings per share
| 2023 | CHF14.39 | 7.34% |
|---|---|---|
| 2024 | CHF16.55 | 15.01% |
| 2025 | CHF18.33 | 10.76% |
| 2026 | CHF19.70 | 7.47% |
| 2027 | CHF21.46 | 8.93% |
| 2028 | CHF22.47 | 4.71% |
P/E ratio
| Current | 17.25 | 2.54% |
|---|---|---|
| 2024 | 15.02 | 12.93% |
| 2025 | 13.56 | 9.72% |
| 2026 | 12.61 | 7.01% |
| 2027 | 11.58 | 8.17% |
| 2028 | 11.06 | 4.49% |
Based on analysts' sales estimates for 2024, the Roche share is valued at an <a href=/blog/ev-sales-einfach-erklaert>EV/Sales of 3.65 and an <a href=/blog/kurs-umsatz-verhaeltnis-kuv-einfach-erklaert>P/S ratio of 3.25 .
This results in the following potential growth figures and future valuations:
EV/Sales
| Current | 3.79 | 0.26% |
|---|---|---|
| 2024 | 3.65 | 3.62% |
| 2025 | 3.45 | 5.57% |
| 2026 | 3.30 | 4.21% |
| 2027 | 3.17 | 4.08% |
| 2028 | 3.06 | 3.37% |
P/S ratio
| Current | 3.37 | 2.32% |
|---|---|---|
| 2024 | 3.25 | 3.54% |
| 2025 | 3.07 | 5.56% |
| 2026 | 2.94 | 4.21% |
| 2027 | 2.82 | 4.08% |
| 2028 | 2.73 | 3.37% |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
